| 3.07 -0.28 (-8.36%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.26  |
1-year : | 14.37 |
| Resists | First : | 7.93 |
Second : | 12.31 |
| Pivot price | 3.87 |
|||
| Supports | First : | 0.85 |
Second : | 0.7 |
| MAs | MA(5) : | 3.46 |
MA(20) : | 3.16 |
| MA(100) : | 3.01 |
MA(250) : | 12 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 15.6 |
D(3) : | 21.5 |
| RSI | RSI(14): 50.8 |
|||
| 52-week | High : | 73 | Low : | 0.82 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MEDS ] has closed above bottom band by 22.2%. Bollinger Bands are 2.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.36 - 3.39 | 3.39 - 3.41 |
| Low: | 2.99 - 3.02 | 3.02 - 3.03 |
| Close: | 3.03 - 3.08 | 3.08 - 3.11 |
DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey.
Tue, 06 Oct 2026
DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue - ACCESS Newswire
Mon, 05 Oct 2026
Eligible DataMeds shareholders can claim 50 digital collectibles per share; they may have no value. - Stock Titan
Fri, 02 Oct 2026
DataMeds AI’s Corexa Pharmacy Surpasses $1 Million In Monthly Revenue - The Killeen Daily Herald
Thu, 01 Oct 2026
MEDS Stock Rockets As DataMeds AI Bets Big On Oncology And GLP‑1 Apps - StocksToTrade
Thu, 01 Oct 2026
DataMeds AI MEDS Stock Soars On Helomics Deal And GLP‑1 App - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Distribution
|
|
| Shares Out | 3 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 56.1 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 165 (K) |
| Shares Short P.Month | 105 (K) |
| EPS | -48.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -6.89 |
| Profit Margin | 0 % |
| Operating Margin | -412.7 % |
| Return on Assets (ttm) | -83 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -77.2 % |
| Gross Profit (p.s.) | -2.38 |
| Sales Per Share | 2.62 |
| EBITDA (p.s.) | -18.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -0.07 |
| PEG Ratio | 0 |
| Price to Book value | -0.45 |
| Price to Sales | 1.17 |
| Price to Cash Flow | -0.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|